Corvus Pharmaceuticals
CRVS
CRVS
48 hedge funds and large institutions have $34.2M invested in Corvus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
8% less funds holding
Funds holding: 52 → 48 (-4)
45% less call options, than puts
Call options by funds: $86K | Put options by funds: $157K
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
48
Holding in Top 10
1
Calls
$86K
Puts
$157K
Top Buyers
| 1 | +$575K | |
| 2 | +$292K | |
| 3 | +$166K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$162K |
| 5 |
SC
Samlyn Capital
New York
|
+$159K |
Top Sellers
| 1 | -$289K | |
| 2 | -$162K | |
| 3 | -$122K | |
| 4 |
Millennium Management
New York
|
-$118K |
| 5 |
Goldman Sachs
New York
|
-$72K |